[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337925-105":59,"doc-detail-337925-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-status-and-future-directions-for-the-development-of-human-papillomavirus-vaccines-review","Current status and future directions for the development of human papillomavirus vaccines - Review","","Human papillomavirus (HPV) vaccine development has achieved major progress, with five prophylactic vaccines approved since 2006, effectively reducing newly acquired infections and HPV-associated malignancies. Despite this success, preventing all HPV infections, eliminating established infections, and blocking progression to cancer remains challenging. The review synthesizes strategies for both prophylactic and therapeutic vaccines, focusing on antigen and adjuvant selection, formulation and dosing schedules, and age expansion informed by preclinical and clinical evidence. It also highlights implications for overcoming uptake barriers such as vaccine hesitancy and availability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-status-and-future-directions-for-the-development-of-human-papillomavirus-vaccines-review/337925/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-status-and-future-directions-for-the-development-of-human-papillomavirus-vaccines-review/337925.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What progress has been made in prophylactic HPV vaccines?","Question",{"text":112,"@type":113},"Five prophylactic HPV vaccines have been approved since 2006, and they are effective at preventing newly acquired infections and reducing HPV-related malignancies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are future directions needed beyond current prophylactic vaccines?",{"text":117,"@type":113},"Prevention of all HPV infections, eradication of established infections, and interruption of progression to cancer are still not fully addressed.",{"name":119,"@type":110,"acceptedAnswer":120},"What strategies does the review emphasize for improving HPV vaccines?",{"text":121,"@type":113},"It emphasizes optimizing prophylactic vaccines by incorporating L1 proteins from more HPV subtypes, exploring adjuvants that strengthen cellular immune responses, and developing therapeutic HPV vaccines alone or combined with other cancer treatments.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337925,1790142133,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","TYPE Review  \nPUBLISHED 25 June 2024  \nDOI 10.3389/fimmu.2024.1362770  \nOPEN ACCESS  \nEDITED BY  \nFabio Bagnoli, GlaxoSmithKline, Italy  \nREVIEWED BY  \nSrinivasa Reddy Bonam,  \nUniversity of Texas Medical Branch at Galveston, United States  \nArash Arashkia,  \nPasteur Institute of Iran (PII), Iran  \n*CORRESPONDENCE Liangzhi Xie  \n [LX@sinocelltech.com](LX@sinocelltech.com)  \n†These authors have contributed equally to this work  \nRECEIVED 29 December 2023  \nACCEPTED 11 June 2024  \nPUBLISHED 25 June 2024  \nCITATION  \nWang R, Huang H, Yu C, Li X, Wang Y and Xie L (2024) Current status and future directions for the development of human papillomavirus vaccines.  \nFront. Immunol. 15:1362770 .  \ndoi: 10.3389/fimmu.2024.1362770  \nCOPYRIGHT  \n© 2024 Wang, Huang, Yu, Li, Wang and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCurrent status and future directions for the development of human papillomavirus vaccines  \nRui Wang 1†, Hongpeng Huang 1†, Chulin Yu 1†, Xuefeng Li 1, Yang Wang 1 and Liangzhi Xie 1,2*  \n1 Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China, 2Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  \nThe development of human papillomavirus (HPV) vaccines has made substantive progress, as represented by the approval of ﬁve prophylactic vaccines since 2006. Generally, the deployment of prophylactic HPV vaccines is effective in preventing newly acquired infections and incidences of HPV-related malignancies. However, there is still a long way to go regarding the prevention of all HPV infections and the eradication of established HPV infections, as well asthe subsequent progression to cancer. Optimizing prophylactic HPV vaccines by incorporating L1 proteins from more HPV subtypes, exploring adjuvants that reinforce cellular immune responses to eradicate HPV-infected cells, and developing therapeutic HPV vaccines used either alone or in combination with other cancer therapeutic modalities might bring about a new era getting closer to the vision to get rid of HPV infection and related diseases. Herein, we summarize strategies for the development of HPV vaccines, both prophylactic and therapeutic, with an emphasis on the selection of antigens and adjuvants, as well as implications for vaccine efﬁcacy based on preclinical studies and clinical trials. Additionally, we outline current cutting-edge insights on formulation strategies, dosing schedules, and age expansion among HPV vaccine recipients, which might play important roles in addressing barriers to vaccine uptake, such as vaccine hesitancy and vaccine availability.  \nKEYWORDS  \nhuman papillomavirus vaccine, prophylactic, therapeutic, antigens, adjuvants, formulation strategy  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nHuman papillomavirus (HPV) infection can cause multiple types of clinical manifestations or diseases such as genital warts, respiratory papillomatosis, head and neck cancer (mostly oropharyngeal squamous cell carcinoma), anal cancer, penile cancer, vulvar cancer, vaginal cancer, and cervical cancer (1, 2) . Among these HPV-associated cancers, cervical cancer contributes to the highest proportion and ranks as the fourth most commonly diagnosed cancer and the fourth leading cause of cancer death in women (3, 4) .  \nDespite the high efﬁcacy demonstrated by prophylactic HPV vaccines and the beneﬁt of cervical screening across the female population, the number of newly diagnosed cervical cancer patients in 2018 was near","cbCaifemOWmX5MFN","https://ap.wps.com/l/cbCaifemOWmX5MFN","pdf",1055277,16,"English","# Introduction\n# Characteristics of human papillomavirus\n## Classification of HPV\n## Genomic characterization of HPV","[{\"question\":\"What progress has been made in prophylactic HPV vaccines?\",\"answer\":\"Five prophylactic HPV vaccines have been approved since 2006, and they are effective at preventing newly acquired infections and reducing HPV-related malignancies.\"},{\"question\":\"Why are future directions needed beyond current prophylactic vaccines?\",\"answer\":\"Prevention of all HPV infections, eradication of established infections, and interruption of progression to cancer are still not fully addressed.\"},{\"question\":\"What strategies does the review emphasize for improving HPV vaccines?\",\"answer\":\"It emphasizes optimizing prophylactic vaccines by incorporating L1 proteins from more HPV subtypes, exploring adjuvants that strengthen cellular immune responses, and developing therapeutic HPV vaccines alone or combined with other cancer treatments.\"}]","Current status and future directions for the development of human papillomavirus vaccines - Review | PDF",1790021201,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dddfed0ce948cc838161fc5cb63a02b3.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dddc8014dfa5c536e81b1c666be45eac.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc90ef25e5d33edc3035ea9e1b1ab749.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1de556b5a7730d467affa26a57a06303.webp",980,1385]